EN DE
STOCK COMPARISON

Merck & Company vs Abbott Laboratories: Fair Value & Quality

Both stocks run through our valuation models. Here is how Merck & Company (MRK) and Abbott Laboratories (ABT) compare, as of Aug 13, 2026.

As of Aug 13, 2026, Fair Value Calculator sees Merck & Company as the less overvalued of the two: Merck & Company trades at $130 versus a fair value of $128 (-2%), while Abbott Laboratories trades at $110 versus $74.79 (-32%).
Merck & Company
MRK · USD · Health Care
-2%
upside to fair value
fairly valued
Price$130
Fair Value$128
Quality70/100
Abbott Laboratories
ABT · USD · Health Care
-32%
upside to fair value
overvalued
Price$110
Fair Value$74.79
Quality67/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Merck & CompanyAbbott Laboratories
Valuation
34.8×P/E (TTM)27.7×
4.64×P/S (TTM)3.89×
5.80×P/B3.36×
11.4×EV/EBITDA15.1×
6.10×PEG1.47×
2.6%Dividend yield
$3.28Dividend per share
Profitability
14%Net margin14%
39%Operating margin13%
19%Return on equity12%
13%Return on assets6%
Growth
5%Revenue growth (YoY)8%
3.1%Avg. growth/yr (3Y)0.5%
9.4%Avg. growth/yr (5Y)5.1%
Balance & size
0.89×Debt / equity0.19×
$305BMarket cap$175B
healthyGrowth qualityhealthy

Abbott Laboratories leads: 6 to 7 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Merck & Companyof which business quality 68 · market factors 84 Abbott Laboratoriesof which business quality 66 · market factors 52
ProfitabilityMargins and returns on capital today
74
50
Quality GrowthAre margins and returns improving?
36
47
CashflowEarnings quality: real cash, not paper profit
65
71
Fin. StrengthBalance sheet, leverage, solvency risk
68
80
InvestmentDisciplined investing over empire-building
71
65
Low VolatilityCalm price path (market factor)
86
83
MomentumPrice trend over the last 3–12 months (market factor)
74
41
52W MomentumDistance to the 52-week high (market factor)
100
36
Net IssuanceBuybacks instead of dilution
91
84

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Merck & Company

DCF Models$117
Earnings-Based$62.77
Dividend Discount$60.35
Multiples$122
Asset-Based$14.27
Growth DCF$74.00
Economic Profit$83.85
Growth Earnings$138

18 of 26 models see the stock below the current price.

Abbott Laboratories

DCF Models$73.01
Earnings-Based$29.42
Dividend Discount$39.73
Multiples$70.72
Asset-Based$20.05
Growth DCF$67.02
Economic Profit$37.49
Growth Earnings$70.25

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Merck & Company
Bear $72.16Fair Value $128Bull $188
$130 = current price (white tick)
Abbott Laboratories
Bear $51.84Fair Value $74.79Bull $94.43
$110 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Merck & Company · Health Care

Quality score70 · Top 25%
Fair value upside-2% · above median

Abbott Laboratories · Health Care

Quality score67 · Top 25%
Fair value upside-32% · below median

Bottom line

As of Aug 13, 2026, Fair Value Calculator sees Merck & Company as the less overvalued of the two: Merck & Company trades at $130 versus a fair value of $128 (-2%), while Abbott Laboratories trades at $110 versus $74.79 (-32%).

Merck & Company has the higher quality score (70/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.